Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Average PT from Brokerages

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have received an average recommendation of “Hold” from the seven research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $55.50.

A number of brokerages recently issued reports on TVRD. Cantor Fitzgerald lowered Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 13th. Raymond James Financial cut Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 14th. Piper Sandler cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. Wall Street Zen downgraded shares of Tvardi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Finally, BTIG Research dropped their price target on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday, October 13th.

Tvardi Therapeutics Stock Performance

Tvardi Therapeutics stock opened at $3.98 on Wednesday. Tvardi Therapeutics has a one year low of $3.74 and a one year high of $43.65. The company has a 50-day simple moving average of $4.56 and a 200-day simple moving average of $20.40. The firm has a market capitalization of $37.33 million, a P/E ratio of -0.41 and a beta of 0.11.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its earnings results on Thursday, November 13th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.24. Tvardi Therapeutics had a negative net margin of 585.37% and a negative return on equity of 282.16%.

Hedge Funds Weigh In On Tvardi Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TVRD. Slate Path Capital LP bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter worth $16,427,000. 683 Capital Management LLC acquired a new position in Tvardi Therapeutics during the second quarter worth about $4,107,000. Vestal Point Capital LP bought a new stake in Tvardi Therapeutics in the third quarter worth about $6,508,000. Geode Capital Management LLC acquired a new stake in Tvardi Therapeutics in the 2nd quarter valued at about $2,617,000. Finally, Invesco Ltd. bought a new position in shares of Tvardi Therapeutics during the 3rd quarter valued at about $3,219,000. 44.66% of the stock is owned by institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.